Abstract

Economic losses due to bovine mastitis is estimated to be $2 billion in the United States alone. Antimicrobials are used extensively in dairy farms for prevention and treatment of mastitis and other diseases of dairy cattle. The use of antimicrobials for treatment and prevention of diseases of dairy cattle needs to be prudent to slow down the development, persistence, and spread of antimicrobial-resistant bacteria from dairy farms to humans, animals, and farm environments. Because of public health and food safety concerns regarding antimicrobial resistance and antimicrobial residues in meat and milk, alternative approaches for disease control are required. These include vaccines, improvements in housing, management practices that reduce the likelihood and effect of infectious diseases, management systems and feed formulation, studies to gain a better understanding of animal behavior, and the development of more probiotics and competitive exclusion products. Monitoring antimicrobial resistance patterns of bacterial isolates from cases of mastitis and dairy farm environments is important for treatment decisions and proper design of antimicrobial-resistance mitigation measures. It also helps to determine emergence, persistence, and potential risk of the spread of antimicrobial-resistant bacteria and resistome from these reservoirs in dairy farms to humans, animals, and farm environments.

Highlights

  • 1.1 Antibiotic use in dairy farms and antimicrobial resistanceEconomic losses due to bovine mastitis is estimated to be $2 billion in the United States alone [1]

  • Some studies showed that the antimicrobial resistance of mastitis pathogens varies with dairy farms and bacterial species within and among dairy farms [4–9]

  • Antimicrobial resistance patterns of human pathogenic bacteria and their resistome in dairy farms might be of significant concern

Read more

Summary

Antibiotic use in dairy farms and antimicrobial resistance

Economic losses due to bovine mastitis is estimated to be $2 billion in the United States alone [1]. Antimicrobials administered through parenteral routes for the treatment of acute or peracute mastitis or other diseases of dairy cows will enter the blood circulation and biotransformed in the liver or kidney and excreted from the body through urine or feces into the environments [39–42] Both parenteral and intramammary administration of antibiotics has a significant impact on other commensals or opportunistic bacteria in the gastrointestinal tract of dairy cows and farm environments. In addition to the use of antimicrobials for the prevention and treatment of mastitis and other diseases of dairy cattle, some farms feed raw waste milk or pasteurized waste milk from antibiotic-treated cows to dairy calves. The prudent use of antimicrobials in dairy farms reduce emergence, persistence, and spread of antimicrobial-resistant bacteria and resistome from dairy farms to human, animal, and environment

Transmission of antimicrobial-resistant bacteria from dairy farms to human
Prospects for effective vaccines against major bacterial mastitis pathogens
Intramammary immune mechanisms
Vaccine trials against Staphylococcus aureus mastitis
Vaccine trials against Streptococcus uberis
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call